SuperworthNeogenomics profit margin NEO
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- −6.8%
- Operating margin, 12 months
- −8.9%
- Net margin on a year earlier
- +8.3 pts
- Peer median
- 5.4%
Over the twelve months to Jun 30, 2026, Neogenomics kept −6.8% of its revenue as net profit, with an operating margin of −8.9% and a gross margin of 43.9%.
Five years earlier its net margin was 14.7%.
The median for 6 specialty Business Services stocks of a similar size is 5.4%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −14.9% | −15.9% | 43.2% |
| FY2024 | −11.9% | −13.9% | 43.9% |
| FY2023 | −14.9% | −18.2% | 41.3% |
| FY2022 | −28.3% | −30.9% | 36.9% |
| FY2021 | −1.7% | −24.5% | 38.6% |
| FY2020 | 0.9% | −3.1% | 41.8% |
| FY2019 | 2.0% | 3.2% | 48.1% |
| FY2018 | 1.0% | 3.6% | 46.0% |
| FY2017 | −0.2% | 1.2% | 42.4% |
| FY2016 | −2.3% | 1.1% | 45.2% |
| FY2015 | −2.5% | −5.6% | 43.8% |
| FY2014 | 1.3% | 2.5% | 46.8% |
| FY2013 | 3.1% | 4.8% | 47.7% |
| FY2012 | 0.1% | 2.0% | 44.8% |
| FY2011 | −2.7% | −0.9% | 44.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −6.8% | +8.3 pts | −8.9% | |
| Q1 FY26 | −13.3% | −1.8 pts | −14.2% | |
| Q4 FY25 | −14.9% | −2.9 pts | −15.9% | |
| Q3 FY25 | −16.0% | −3.9 pts | −17.0% | |
| Q2 FY25 | −15.1% | −2.6 pts | −16.7% | |
| Q1 FY25 | −11.5% | +2.3 pts | −13.3% | |
| Q4 FY24 | −11.9% | +3.0 pts | −13.9% | |
| Q3 FY24 | −12.1% | +4.7 pts | −14.3% | |
| Q2 FY24 | −12.5% | +8.3 pts | −15.2% | |
| Q1 FY24 | −13.8% | +9.9 pts | −16.9% | |
| Q4 FY23 | −14.9% | +13.4 pts | −18.2% | |
| Q3 FY23 | −16.8% | +16.1 pts | −20.1% |
Against its peers
Companies in Specialty Business Services nearest Neogenomics' size, closest first, today.
| Company | Profit margin |
|---|---|
| NEONeogenomics | −6.8% |
| VVXV2X | 1.9% |
| MHMcGraw Hill | 4.4% |
| DFINDonnelley Financial Solutions | 4.5% |
| CRAICRA International | 6.2% |
| ITGartner | 12.0% |
| ULSUL Solutions | 16.1% |
| Peer median | 5.4% |
Where Neogenomics ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Neogenomics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.